Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Molecules ; 23(8)2018 Jul 28.
Artículo en Inglés | MEDLINE | ID: mdl-30060551

RESUMEN

BACKGROUND: The use of resveratrol as a dietary supplement is limited because it is easily oxidized and, after oral ingestion, it is metabolized into enterocytes and hepatocytes. Thus, new formulations are needed in order to improve its oral bioavailability. OBJECTIVE: The objective of this study was to develop and characterize a gastro-resistant formulation of resveratrol for oral administration as a dietary supplement. METHOD: Resveratrol was encapsulated in Eudragit-coated pectin-alginate microparticles. RESULTS: The microparticle size was about 1450 µm, with an encapsulation efficiency of 41.72% ± 1.92%. The dissolution assay conducted, as specified in the European Pharmacopoeia for delayed-release dosage forms, revealed that our microparticles were gastro-resistant, because the resveratrol percentage released from microparticles in acid medium was less than 10%. In addition, the high-performance liquid chromatographic (HPLC) method developed for resveratrol content quantification in the microparticles was validated according to International Council for Harmonisation (ICH) Q2 (R1) guidelines. Finally, the biological activity of resveratrol was investigated in 3T3-L1 mature adipocytes, concluding that the encapsulation process does not affect the activity of resveratrol. CONCLUSION: In summary, the gastro-resistant microparticles developed could represent a suitable method of including resveratrol in dietary supplements and in functional foods used in obesity therapy.


Asunto(s)
Alginatos/química , Fármacos Antiobesidad/farmacología , Preparaciones de Acción Retardada , Pectinas/química , Estilbenos/farmacología , Triglicéridos/antagonistas & inhibidores , Células 3T3-L1 , Adipocitos/citología , Adipocitos/efectos de los fármacos , Adipocitos/metabolismo , Animales , Fármacos Antiobesidad/metabolismo , Materiales Biomiméticos/química , Materiales Biomiméticos/farmacología , Cápsulas , Diferenciación Celular , Suplementos Dietéticos/análisis , Composición de Medicamentos/métodos , Liberación de Fármacos/efectos de los fármacos , Jugo Gástrico/química , Ácido Glucurónico/química , Ácidos Hexurónicos/química , Humanos , Concentración de Iones de Hidrógeno , Cinética , Ratones , Tamaño de la Partícula , Ácidos Polimetacrílicos/química , Resveratrol , Estilbenos/metabolismo , Triglicéridos/biosíntesis
2.
World J Gastroenterol ; 20(23): 7366-80, 2014 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-24966607

RESUMEN

Non-alcoholic fatty liver disease covers a wide spectrum of liver pathologies which range from simple steatosis to non-alcoholic steatohepatitis. Polyphenols are members of a very large family of plant-derived compounds that can have beneficial effects on human health, and thus their study has become an increasingly important area of human nutrition research. The aim of the present review is to compile published data concerning the effects of both isolated polyphenols as well as polyphenol extracts, on hepatocyte and liver fat accumulation under different steatosis-inducing conditions. The results reported clearly show that this group of biomolecules is able to reduce fat accumulation, but further studies are needed to establish the optimal dose and treatment period length. With regard to the potential mechanisms of action, there is a good consensus. The anti-lipidogenic effect of polyphenols is mainly due to reduced fatty acid and triacylglycerol synthesis, increased in fatty acid oxidation, and reduced of oxidative stress and inflammation. As a general conclusion, it can be stated that polyphenols are biomolecules which produce hepatoprotective effects. To date, these beneficial effects have been demonstrated in cultured cells and animal models. Thus, studies performed in humans are needed before these molecules can be considered as truly useful tools in the prevention of liver steatosis.


Asunto(s)
Hipolipemiantes/uso terapéutico , Hígado/efectos de los fármacos , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Polifenoles/uso terapéutico , Estilbenos/uso terapéutico , Animales , Antiinflamatorios/uso terapéutico , Antioxidantes/uso terapéutico , Humanos , Metabolismo de los Lípidos/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Hígado/fisiopatología , Enfermedad del Hígado Graso no Alcohólico/diagnóstico , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Enfermedad del Hígado Graso no Alcohólico/fisiopatología , Fitoterapia , Plantas Medicinales , Quercetina/uso terapéutico , Resveratrol , Resultado del Tratamiento
3.
J Physiol Biochem ; 67(3): 471-7, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21455758

RESUMEN

Scientific research is constantly looking for new molecules to be used as functional ingredients to combat obesity. The aim of the present study was to analyse whether resveratrol and conjugated linoleic acid (CLA) together could reduce body fat more efficiently than their separate administration. Thirty-six male Wistar rats were randomly divided into four groups: controls rats (C), rats treated with resveratrol (RSV), rats treated with CLA (CLA) and rats treated with a combination of resveratrol and CLA (RSV+CLA). All rats were fed on an obesogenic diet. In RSV and RSV+CLA groups, the rats received 30 mg resveratrol/kg body weight/day. In CLA and RSV+CLA groups, an equimolecular mixture of trans-10,cis-12 and cis-9,trans-11 was added to the diet to reach 0.5% of the active isomer trans-10,cis-12. After 6 weeks of treatment, white adipose tissue from different anatomical locations was dissected and weighed. Serum triacylglycerols, total and HDL cholesterols, glucose, insulin, fructosamine and TNF-α were measured. A glucose tolerance test was also performed. Separately, resveratrol and CLA significantly reduced body fat but did not do so when combined: 20% in the RSV group and 18% in CLA group but 7% in the RSV+CLA group. Resveratrol reduced serum triacylglycerols. No differences were found among groups in serum cholesterol. Resveratrol, as well as the combination RSV+CLA, improved glycaemic control. These results demonstrate that the combination RSV+CLA reduces the effectiveness of each compound on body fat-lowering action, but it maintains the positive effect of resveratrol on glycaemic control. Consequently, this combination has no usefulness in obesity prevention.


Asunto(s)
Ácidos Linoleicos Conjugados/farmacología , Obesidad/prevención & control , Estilbenos/farmacología , Tejido Adiposo Blanco/metabolismo , Tejido Adiposo Blanco/patología , Animales , Área Bajo la Curva , Glucemia , Peso Corporal/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada , Ingestión de Energía/efectos de los fármacos , Prueba de Tolerancia a la Glucosa , Lípidos/sangre , Masculino , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Wistar , Resveratrol , Insuficiencia del Tratamiento
4.
Nutrition ; 27(1): 116-121, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20619605

RESUMEN

OBJECTIVE: Little evidence exists concerning the effects of trans-10,cis-12 conjugated linoleic acid (CLA) under energy restriction. Thus, the effects of this CLA isomer on adipose tissue size, liver composition, as well as on expression and activity of carnitine-palmitoyl transferase I (CPT-I) and acyl CoA oxidase (ACO), in hamsters fed an energy-restricted diet were analyzed. METHODS: Hamsters were fed a high-fat diet for 7 wk and then subjected to 25% energy-restricted diets supplemented with 0.5% linoleic acid or 0.5% trans-10,cis-12 CLA for 3 wk. Serum insulin, free-triiodothyronine and non-esterified fatty acid levels, liver triacylglycerol, protein and water contents, and CPT-I, ACO, and Peroxisome proliferator-activated receptor alpha (PPARα) expressions and enzyme activities were assessed. RESULTS: Energy restriction reduced liver size, serum levels of insulin, free-triiodothyronine, and non-esterified fatty acid and increased CPT-I activity. Liver composition was not modified. No differences were found between both restricted groups, with the exception of CPT-I and ACO oxidative enzyme activities, which were greater in hamsters fed the CLA diet. CONCLUSIONS: Energy restriction does not cause trans-10,cis-12 CLA to induce liver hyperplasia. Although this CLA isomer increases liver CPT-I and ACO activities, this effect does not result in reduced hepatic triacylglyerol content or decreased adipose tissue size. Consequently, this CLA isomer seems not to be a useful tool for inclusion in body weight loss strategies followed during obesity treatment.


Asunto(s)
Acil-CoA Oxidasa/metabolismo , Restricción Calórica , Carnitina O-Palmitoiltransferasa/metabolismo , Ácidos Linoleicos Conjugados/farmacología , Peroxidación de Lípido/efectos de los fármacos , Hígado/efectos de los fármacos , Obesidad/tratamiento farmacológico , Animales , Cricetinae , Grasas de la Dieta/efectos adversos , Suplementos Dietéticos , Ácidos Grasos no Esterificados/sangre , Hiperplasia , Insulina/sangre , Isomerismo , Ácido Linoleico/farmacología , Hígado/metabolismo , Hígado/patología , Masculino , Mesocricetus , Obesidad/metabolismo , Obesidad/patología , Triyodotironina/sangre
5.
Br J Nutr ; 102(11): 1583-9, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19619365

RESUMEN

It has been proposed that young animals and subjects are more responsive to conjugated linoleic acid (CLA) than the adults. Nevertheless, there is very little information concerning the effectiveness of CLA in adult animals. In the present study we aimed to explore the effects of trans-10, cis-12-CLA on body fat accumulation in adult hamsters, as well as on some of the molecular mechanisms described in young animals as responsible for the CLA body fat-lowering effect, such as lipogenesis, lipoprotein lipase (LPL)-mediated fat uptake and thermogenesis. The experiment was conducted with sixteen adult male Syrian Golden hamsters (aged 8 months) fed a high-fat diet supplemented or not with 0.5 % trans-10, cis-12-CLA for 6 weeks. Acetyl-CoA carboxylase (ACX), fatty acid synthase (FAS), LPL, PPARgamma, sterol regulatory element-binding protein (SREBP)-1a and SREBP-1c expressions were assessed in subcutaneous and perirenal adipose tissues by real-time RT-PCR. Total and heparin-releasable LPL activities were determined in subcutaneous adipose tissue by fluorimetry and FAS activity by spectrophotometry. Uncoupling protein-1 (UCP1) expression in interscapular brown adipose tissue was assessed by Western blot. Hamsters fed the trans-10, cis-12-CLA diet showed a significant reduction in subcutaneous adipose tissue. No changes were observed in the expression of ACX, FAS, LPL, SREBP-1a, SREBP-1c and PPARgamma, nor in total and heparin-releasable LPL and FAS activities. Trans-10, cis-12-CLA induced a significant increase in the amount of UCP1. These results suggest a low responsiveness to trans-10, cis-12-CLA in adults, lower than that in young hamsters. One of the reasons explaining this difference is the lack of effect on LPL.


Asunto(s)
Tejido Adiposo/efectos de los fármacos , Ácidos Linoleicos Conjugados/farmacología , Tejido Adiposo/enzimología , Tejido Adiposo Pardo/efectos de los fármacos , Tejido Adiposo Pardo/metabolismo , Tejido Adiposo Blanco/efectos de los fármacos , Tejido Adiposo Blanco/enzimología , Animales , Peso Corporal/efectos de los fármacos , Peso Corporal/fisiología , Cricetinae , Ingestión de Alimentos/efectos de los fármacos , Ingestión de Alimentos/fisiología , Regulación Enzimológica de la Expresión Génica , Canales Iónicos/metabolismo , Lipogénesis/efectos de los fármacos , Masculino , Mesocricetus , Proteínas Mitocondriales/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Grasa Subcutánea/enzimología , Factores de Transcripción/metabolismo , Proteína Desacopladora 1
6.
J Am Coll Nutr ; 28(6): 627-35, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20516262

RESUMEN

OBJECTIVE: To analyze the effects of high-fat high-sucrose (HFHS) feeding, energy restriction, and trans-10,cis-12 conjugated linoleic acid (CLA) on visfatin and apelin. DESIGN: A randomized dietary intervention study. SETTING: Free-living individuals studied in metabolic cages. SUBJECTS: Thirty-two male Syrian Golden hamsters (82.6 +/- 1.4 g). INTERVENTIONS: Standard and HFHS feeding for 7 weeks. After that, some hamsters fed the HFHS diet were submitted for 3 weeks to a 25% energy restriction with or without trans-10,cis-12 CLA supplementation (0.5%). RESULTS: Feeding animals an HFHS diet resulted in increased body fat and reduced insulin sensitivity. No changes were observed in the expression and serum levels of visfatin and apelin, or in peroxisome proliferator-activated receptor (PPAR)gamma and Sirt1 expression. Energy restriction reduced body fat and normalized insulin sensitivity. Visfatin showed increased serum levels without changes in expression. No modifications were found as far as apelin was concerned. Sirt1 expression was increased, and PPARgamma remained unchanged. With regard to trans-10,cis-12 CLA, no changes were induced by its addition to the restricted diet. CONCLUSIONS: Insulin function impairment induced by HFHS feeding is not mediated by visfatin and apelin. However, visfatin can play a role in improving insulin sensitivity associated with energy restriction. These results suggest that visfatin may not have evolved as a molecule that reserves the action of insulin when food is widely available, but rather that its function seems to be associated with energy restriction adaptation. In general terms, trans-10,cis-12 CLA did not modify changes induced by energy restriction.


Asunto(s)
Tejido Adiposo/metabolismo , Proteínas Portadoras/metabolismo , Grasas de la Dieta/administración & dosificación , Sacarosa en la Dieta/administración & dosificación , Ácido Linoleico/administración & dosificación , Nicotinamida Fosforribosiltransferasa/metabolismo , Tejido Adiposo/efectos de los fármacos , Análisis de Varianza , Animales , Peso Corporal/efectos de los fármacos , Proteínas Portadoras/genética , Cricetinae , Ensayo de Inmunoadsorción Enzimática , Insulina/sangre , Resistencia a la Insulina/fisiología , Leptina/sangre , Masculino , Mesocricetus , Nicotinamida Fosforribosiltransferasa/genética , PPAR gamma/genética , PPAR gamma/metabolismo , Distribución Aleatoria , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
7.
Br J Nutr ; 100(6): 1245-50, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18507880

RESUMEN

Very little evidence exists concerning the effects of conjugated linoleic acid (CLA) on body fat reduction induced by energy restriction. Moreover, although an effect of trans-10, cis-12-CLA on lipolysis has been suggested, it has not been consistently shown. The aims of the present study were to determine whether trans-10, cis-12-CLA increases the reduction of body fat induced by energy restriction, and to analyse its effect on lipolysis and adipose tissue lipase expression (hormone-sensitive lipase (HSL) and adipose tissue TAG lipase (ATGL)). Male Syrian Golden hamsters were fed a high-fat diet during 7 weeks in order to make them fatter. Then they were submitted to a mild energy restriction (25 %) without or with supplementation of 0.5 % trans-10, cis-12-CLA for 3 weeks. Basal glycerol release and lipolysis stimulated by several drugs acting at different levels of the lipolytic cascade were measured in epididymal adipose tissue. The expression of HSL and ATGL was assessed by real-time RT-PCR. No differences were found in adipose tissues size between the experimental groups. Medium adipocyte size and total number of adipocytes were similar in both experimental groups. Animals fed the CLA-enriched diet showed similar lipolytic rates as well as HSL and ATGL expressions to the controls. In conclusion, trans-10, cis-12-CLA does not promote adipose tissue lipid mobilisation nor does it heighten body fat reduction induced by energy restriction. Consequently, this CLA isomer does not seem to be a useful tool to be included in body weight-loss strategies followed in obesity treatment.


Asunto(s)
Adiposidad/efectos de los fármacos , Restricción Calórica , Ácidos Linoleicos Conjugados/farmacología , Lipólisis/efectos de los fármacos , Adipocitos/efectos de los fármacos , Tejido Adiposo/anatomía & histología , Tejido Adiposo/efectos de los fármacos , Tejido Adiposo/enzimología , Animales , Tamaño de la Célula/efectos de los fármacos , Cricetinae , Evaluación Preclínica de Medicamentos/métodos , Lipasa/metabolismo , Masculino , Mesocricetus , Pérdida de Peso/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA